Qube Research & Technologies (QRT)
ZNTL icon

Qube Research & Technologies (QRT)’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.79M Sell
574,806
-62,310
-10% -$249K ﹤0.01% 1967
2026
Q1 		$1.49M Buy
637,116
+619,645
+3,547% +$1.6M ﹤0.01% 2316
2025
Q4 		$23.6K Sell
17,471
-39,168
-69% -$57K ﹤0.01% 3364
2025
Q3 		$85.5K Buy
56,639
+24,526
+76% +$36.8K ﹤0.01% 3096
2025
Q2 		$37.3K Buy
+32,113
New +$42.4K ﹤0.01% 3194
2024
Q1 		– Sell
-50,202
Closed -$761K – 4945
2023
Q4 		$761K Sell
50,202
-91,186
-64% -$1.33M ﹤0.01% 2070
2023
Q3 		$2.84M Buy
+141,388
New +$3.59M 0.01% 1198
2022
Q2 		– Sell
-15,177
Closed -$700K – 3222
2022
Q1 		$700K Buy
15,177
+6,363
+72% +$343K 0.01% 1363
2021
Q4 		$741K Sell
8,814
-620
-7% -$48K 0.01% 1357
2021
Q3 		$629K Buy
9,434
+3,949
+72% +$228K 0.01% 1105
2021
Q2 		$292K Buy
+5,485
New +$294K ﹤0.01% 1598

Other funds holding ZNTL

5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Qube Research & Technologies (QRT)'s ZNTL Position: Q2 2026 in Review

Qube Research & Technologies (QRT) reduced its Zentalis Pharmaceuticals (ZNTL) stake by 9.8% in Q2 2026, selling an estimated $249K and leaving 574,806 shares worth $2.79M. The position accounts for ﹤0.01% of the portfolio, ranked #1967.

Qube Research & Technologies (QRT) first reported a position in ZNTL in Q2 2021 and has held it in 11 quarters since. The position peaked at $2.84M in Q3 2023. 114 funds tracked by Wall St. Rank hold ZNTL as of Q2 2026.

  • Qube Research & Technologies (QRT) held 574,806 shares of Zentalis Pharmaceuticals worth $2.79M as of Q2 2026.
  • Qube Research & Technologies (QRT) sold 62,310 Zentalis Pharmaceuticals shares in Q2 2026, an estimated $249K.
  • Zentalis Pharmaceuticals made up ﹤0.01% of Qube Research & Technologies (QRT)'s portfolio in Q2 2026, its #1967 holding.
  • Qube Research & Technologies (QRT) first reported a position in Zentalis Pharmaceuticals in Q2 2021 and has held it in 11 quarters since.
  • Qube Research & Technologies (QRT)'s Zentalis Pharmaceuticals position peaked at $2.84M in Q3 2023.
  • 114 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q2 2026.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q2 2026, filed 14 Aug 2026.